Literature DB >> 8937839

The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance.

R N Jones1.   

Abstract

The American Society for Microbiology (ASM) convened a task force to study the current prevelance of antibiotic resistance and the problems associated with it. The task force produced a series of recommendations centered around three key elements: (a) education of the physician and the public; (b) encouragement of more basic research directed to the development of new antimicrobials and vaccines; and (c) the setting-up of a national surveillance system to both confirm and monitor the extent of the problem. Since the publication of this report in 1995, progress has been slow. No "consortium-style" funding has been set aside and any initiatives, such as the first steps in an education program by the ASM, are still in their planning phases. The spirit of cooperation and trust needed to deal with this problem appears to be lacking.

Mesh:

Substances:

Year:  1996        PMID: 8937839     DOI: 10.1016/s0732-8893(96)00099-5

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  17 in total

Review 1.  Reality of developing a community-wide antibiogram.

Authors:  Diane C Halstead; Noel Gomez; Yvette S McCarter
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

2.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

3.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  FDA-CDC Antimicrobial Resistance Isolate Bank: a Publicly Available Resource To Support Research, Development, and Regulatory Requirements.

Authors:  Joseph D Lutgring; María-José Machado; Faiza H Benahmed; Patricia Conville; Ribhi M Shawar; Jean Patel; Allison C Brown
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

6.  Fungemia Surveillance in Denmark Demonstrates Emergence of Non-albicans Candida Species and Higher Antifungal Usage and Resistance Rates than in Other Nations.

Authors:  Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

7.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

8.  Multidrug and Mupirocin Resistance in Environmental Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates from Homes of People Diagnosed with Community-Onset MRSA Infection.

Authors:  J H Shahbazian; P D Hahn; S Ludwig; J Ferguson; P Baron; A Christ; K Spicer; P Tolomeo; A M Torrie; W B Bilker; V C Cluzet; B Hu; K Julian; I Nachamkin; S C Rankin; D O Morris; E Lautenbach; M F Davis
Journal:  Appl Environ Microbiol       Date:  2017-10-31       Impact factor: 4.792

9.  Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates.

Authors:  Leonard E Weisman; Helen M Thackray; Joseph A Garcia-Prats; Mirjana Nesin; Joseph H Schneider; Jennifer Fretz; John F Kokai-Kun; James J Mond; William G Kramer; Gerald W Fischer
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

10.  Curbing the menace of antimicrobial resistance in developing countries.

Authors:  Chidi Victor Nweneka; Ndey Tapha-Sosseh; Anibal Sosa
Journal:  Harm Reduct J       Date:  2009-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.